Sintana Announces Amendments to its By-Laws <!-- Twitter Tags --> <!-- Facebook Tags --> <!-- Injecting site-wide to the head --> <!-- End Injecting site-wide to the head --><!-- Inject secured cdn script --> <!-- ========= Meta Tags ========= --> <!-- PWA settings --> <!-- Add manifest --> <!-- End PWA settings --> <!--Add favorites icons--><!-- End favorite icons --> <!-- render the required CSS and JS in the head section --> <!-- loadCSS function header.jsp--> <!-- Google Fonts Include --><!-- loadCSS fu ...

SG&A also included CAD 1.2 million tied to a litigation settlement with a former company executive related to a claim launched in 2020.SG&A increased in part due to CAD 2.9 million of costs related to the Bozzetto transaction.Leonard said consolidated revenue declined in Q4 2025 due to lower volumes and pricing pressure in both core businesses, though gross profit margins held due to improvements in mix. As a result, adjusted EBITDA was down CAD 0.6 million year-over-year for the quarter, according to manag ...

Shares of AIM ImmunoTech Inc. (AIM) are climbing about 80 percent on Wednesday morning trading after the Japan Patent Office approved a Japanese patent covering the company's proprietary use of Ampligen (rintatolimod) in combination with checkpoint inhibitors for the treatment of cancer.The company's shares are currently trading at $1.28 on the New York Stock Exchange American, up 80.28 percent. The stock opened at $1.45 and has climbed as high as $1.62 so far in today's session. Over the past year, it has ...

DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- Today’s action highlights biotech and healthcare innovators advancing novel therapies and strategic platforms amid rising demand for targeted treatments and efficient global access. With the biologics market surging toward $650 billion+ by 2030 and medical tourism accelerating, today's developments showcase capital-efficient clinical progress, high-growth partnerships, and operational scaling, creating compelling narratives in precision medicine, oncology adjuvants ...

Core Viewpoint - AIM ImmunoTech Inc. has received full approval for a Japanese patent covering the use of Ampligen in combination with checkpoint inhibitors for cancer treatment, particularly pancreatic cancer, which is expected to see a significant increase in burden by 2030 [1][2]. Group 1: Patent and Intellectual Property - The Japanese patent covers the use of Ampligen in combination with checkpoint inhibitors for treating various cancer types, including pancreatic cancer [2]. - AIM holds additional patents in the U.S. and the Netherlands for similar uses of Ampligen, with expiration dates in August 2039 and December 2039, respectively [2]. - The company plans to expand its intellectual property portfolio by pursuing orphan drug designation in Japan for Ampligen in treating pancreatic cancer, complementing existing designations in the U.S. and EU [3]. Group 2: Market Context and Strategy - Japan is identified as a key global market for health, with significant expected increases in pancreatic cancer cases by 2030 [1]. - The company emphasizes its commitment to developing Ampligen for late-stage pancreatic cancer, addressing a critical unmet health need [3]. - The patent's approval is part of AIM's broader development and commercialization strategy [3]. Group 3: Product Information - Ampligen (rintatolimod) is described as a dsRNA and highly selective TLR3 agonist immuno-modulator that has demonstrated broad-spectrum activity in clinical trials [4].

Core Viewpoint - AIM ImmunoTech Inc. has successfully closed its rights offering, raising approximately $1.8 million to support the development of its lead product, Ampligen® (rintatolimod), aimed at treating late-stage pancreatic cancer, a significant global health issue [1][5]. Group 1: Rights Offering Details - The rights offering allowed holders to purchase one unit at a subscription price of $1,000, which included one share of Series G Convertible Preferred Stock and 2,000 Class G Common Stock Purchase Warrants [2]. - Maxim Group LLC served as the dealer-manager for the rights offering [2]. Group 2: Regulatory Information - The registration statement for the rights offering was declared effective by the SEC on February 10, 2026, with modifications made in a prospectus supplement filed on February 27, 2026 [3]. - The prospectus detailing the terms of the rights offering is available on the SEC's website [3]. Group 3: Company Overview - AIM ImmunoTech Inc. focuses on the research and development of Ampligen®, which is a dsRNA and selective TLR3 agonist immuno-modulator showing broad-spectrum activity in clinical trials for late-stage pancreatic cancer [5].

Core Viewpoint - AIM ImmunoTech Inc. has announced preliminary results of its rights offering, estimating total subscriptions of approximately $1.8 million, aimed at funding the development of its lead product, Ampligen® for late-stage pancreatic cancer treatment [1][3]. Group 1: Rights Offering Details - The rights offering allowed holders to purchase one unit at a subscription price of $1,000, which included one share of Series G Convertible Preferred Stock and 2,000 Class G Common Stock Purchase Warrants [2]. - The closing of the rights offering is anticipated to occur on or about March 6, 2026, pending the satisfaction of all closing conditions [3]. Group 2: Company Overview - AIM ImmunoTech Inc. is focused on the research and development of Ampligen® (rintatolimod), an immuno-modulator that has shown broad-spectrum activity in clinical trials for treating late-stage pancreatic cancer, a significant global health issue [7].

Core Viewpoint - Nike Circuit has partnered with AIM Sports Group as its exclusive digital partner, enhancing the youth sports experience through AIM+ until summer 2027 [1] Group 1: Partnership Details - AIM Sports Group will provide a fully integrated digital ecosystem, AIM+, at all Nike Circuit events [1] - The partnership aims to transform the youth sports experience for players, coaches, parents, fans, and recruiters [1] Group 2: Future Outlook - The collaboration will continue through the summer of 2027, indicating a long-term commitment to improving youth sports [1]

OCALA, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced an agreement with the PPD™ clinical research business of Thermo Fisher Scientific to design AIM’s anticipated Phase 3 clinical trial in the use of the Company’s drug Ampligen in the treatment of late-stage pancreatic cancer. AIM CEO Thomas K. Equels states: “The ongoing Phase 2 DURIPANC clinical trial of Ampligen and AstraZeneca’s durvalumab in the treatment of late-stage pancrea ...

Core Viewpoint - AIM ImmunoTech Inc. is conducting a rights offering to raise funds for the development of its lead product, Ampligen® (rintatolimod), aimed at treating late-stage pancreatic cancer, which is a significant global health issue [1][8]. Rights Offering Details - Each subscription right allows holders to purchase one unit, consisting of one share of Series G Convertible Preferred Stock and 2,000 Class G Common Stock Purchase Warrants, at a subscription price of $1,000 per unit [2]. - The Preferred Stock is convertible into 1,000 shares of Common Stock at the holder's option, with a conversion price of $1.00 per share [2]. - Each Warrant can be exercised for one share of Common Stock at an exercise price of $1.00 per share, valid for five years from issuance [2]. Participation Requirements - Record holders wishing to participate must submit a completed rights certificate and payment to the Subscription Agent by 5:00 p.m. Eastern Time on March 3, 2026 [3]. - Subscription rights are non-transferable and cannot be revoked once exercised [4]. Management and Regulatory Aspects - Maxim Group LLC has been appointed as the dealer-manager for the Rights Offering [5]. - The offering is conducted under a registration statement declared effective by the SEC on February 10, 2026, and is available through the SEC's website [6]. Company Overview - AIM ImmunoTech Inc. focuses on immuno-pharmaceutical research and development, particularly for Ampligen®, which is a dsRNA and selective TLR3 agonist with demonstrated activity in clinical trials [8][9].